Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in People Living With HIV on Antiretroviral Therapy
NCT05668026Phase 2Recruiting
- Sponsor
- Aarhus University
- Start
- Apr 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in human immunodeficiency virus infection (HIV), sponsored by Aarhus University. Primary endpoint: Safety of venetoclax at 140 days. Started Apr 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05668026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668026.